



## Liste des publications IUCT-O/CRCT

Juillet 2021

Version du 27 septembre 2021

(IF 2020)

Un **nouvel indicateur** a été développé par **Clarivate Analytics**, et est désormais disponible pour toutes les publications intégrées dans Web of Science. Intitulée **Journal Citation Report**, cette mesure représente l'**impact moyen des citations, normalisé par catégorie, pour les articles publiés dans les 3 précédentes années**. Il permet notamment de fournir un indicateur à des journaux ne possédant pas encore de facteur d'impact. Nous l'avons ajouté dans la liste ci-dessous pour les articles « NC ». [En savoir plus](#)

1. Akladios, C., Bendifallah, S., Deluche, E., Betrian, S., Espenel, S., Jochum, F., Babin, G., Guyon, F., 2021. [**Reprint of: SFOG Campus, A new group is born!**]. Bull Cancer S0007-4551(21)00179-X. <https://doi.org/10.1016/j.bulcan.2020.10.024> – IF : **1.276 (cat E, Q4)**
2. Anderson, K.C., Auclair, D., Adam, S.J., Agarwal, A., Anderson, M., Avet-Loiseau, H., Bustoros, M., Chapman, J., Connors, D.E., Dash, A., Di Bacco, A., Du, L., Facon, T., Flores-Montero, J., Gay, F., Ghobrial, I.M., Gormley, N.J., Gupta, I., Higley, H., Hillengass, J., Kanapuru, B., Kazandjian, D., Kelloff, G.J., Kirsch, I.R., Kremer, B.E., Landgren, O., Lightbody, E.D., Lomas, O.C., Lonial, S., Mateos, M.V., Montes de Oca, R., Mukundan, L., Munshi, N.C., O'Donnell, E.K., Orfao, A., Paiva, B., Patel, R., Pugh, T.J., Ramasamy, K., Ray, J., Roshal, M., Ross, J.A., Sigman, C.C., Thoren, K.L., Trudel, S., Ulaner, G.A., Valente, N., Weiss, B.M., Zamagni, E., Kumar, S.K., 2021. **Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration**. Clin Cancer Res clincanres.1059.2021. <https://doi.org/10.1158/1078-0432.CCR-21-1059> - IF : **12.531 (cat A, Q1)**
3. Barraud, S., Caron, P., Raingeard, I., Lefebvre, H., Raverot, G., Cortet-Rudelli, C., Desailoud, R., Henocque, R., Brault, Y., Brue, T., Chanson, P., Delemer, B., 2021. **Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients)**. Ann Endocrinol (Paris) S0003-4266(21)00078-0. <https://doi.org/10.1016/j.ando.2021.05.004> - IF : **2.478 (cat E, Q4)**

4. Barré, T., Ramier, C., Di Beo, V., Carrat, F., Fontaine, H., Marcellin, F., Carrieri, P., Pol, S., Protopopescu, C., ANRS/AFEF Hepather study group, 2021, [collab : Bonnet, D.]. **Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association?** (ANRS CO22 HEPATHER). *Liver Int* 41, 1694–1698. <https://doi.org/10.1111/liv.14949> – *IF : 5.828 (cat C, Q2)*
  
5. Belhabib, I., Zaghdoudi, S., Lac, C., Bousquet, C. & Jean, C., 2021. **Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?** *Cancers (Basel)* 13, 3466. <https://doi.org/10.3390/cancers13143466> - *IF : 6.639 (cat B, Q1)*
  
6. Beugniez, C., Sauvanet, A., Sulpice, L., Gaujoux, S., Turrini, O., Truant, S., Schwarz, L., Piessen, G., Regimbeau, J.M., Muscari, F., Adham, M., Pattou, F., Schneider, L., Clement, G., Delpero, J.-R., Pruvot, F.-R., Amrani, M.E., And French-ACHBT Working Group, 2021. **Root-Cause Analysis of Mortality Following Pancreatic Resection (CARE Study): A Multicenter Cohort Study.** *Ann Surg.* <https://doi.org/10.1097/SLA.0000000000005118> - *IF : 12.969 (cat A, Q1)*
  
7. Bezombes, C & Pérez-Galán, P., 2021. **Immunotherapies in Non-Hodgkin's Lymphoma.** *Cancers (Basel)* 13, 3625. <https://doi.org/10.3390/cancers13143625> - *IF : 6.639 (cat B, Q1)*
  
8. Bouthemy, C., Ralazamahaleo, M., Cargou, M., Fort, M., Congy-Jolivet, N., 2021. **Identification of the novel HLA-DQB1\*06:386 allele by next-generation sequencing.** *HLA.* <https://doi.org/10.1111/tan.14376> - *IF : 4.513 (cat B, Q1)*
  
9. Brito, A., Merle, C., Lagarde, P., Faustin, B., Devin, A., Lartigue, L. & Chibon, F., 2021. **Cell fusion enhances energy metabolism of mesenchymal tumor hybrid cells to sustain their proliferation and invasion.** *BMC Cancer* 21, 863. <https://doi.org/10.1186/s12885-021-08561-6> – *IF : 4.43 (cat C, Q2)*
  
10. Campana, F., Lan, R., Girard, C., Rochefort, J., Le Pelletier, F., Leroux-Villet, C., Mares, S., Millot, S., Zlowodzki, A.-S., Sibaud, V., Tessier, M.-H., Vaillant, L., Fricain, J.-C., Samimi, M., 2021. **French guidelines for the management of oral lichen planus (excluding pharmacological therapy).** *Ann Dermatol Venereol* S0151-9638(21)00052–1. <https://doi.org/10.1016/j.annder.2021.04.003> – *IF : 0.777 (cat E, Q4)*
  
11. Cano, L., Bertani, S., Island, M.-L., Cerapio, J.P., Ruiz, E., Pineau, P., Monbet, V., Boudjema, K., Taxa, L., Casavilca-Zambrano, S., Ropert, M., Turlin, B., Loréal, O., 2021. **Metallomic profile in non-cirrhotic hepatocellular carcinoma supports a**

**phenomenon of metal metabolism adaptation in tumor cells.** Sci Rep 11, 14195.  
<https://doi.org/10.1038/s41598-021-93369-4> - IF : 4.379 (cat B, Q1)

12. Cavo, M., San-Miguel, J.F.F., Usmani, S.Z., Weisel, K.C., Dimopoulos, M.A.A., Avet-Loiseau, H., Paiva, B., Bahlis, N.J., Plesner, T., Hungria, V.T. de M., Moreau, P., Mateos, M.V., Perrot, A., Iida, S., Facon, T., Kumar, S.K., van de Donk, N.W.C.J., Sonneveld, P., Spencer, A., Krevvata, M., Heuck, C., Wang, J., Ukropec, J., Kobos, R., Sun, S., Qi, M., Munshi, N.C., 2021. **Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA.** Blood blood.2021011101. <https://doi.org/10.1182/blood.2021011101> – IF : 22.113 (cat A, Q1)
13. Chabrilac, E., Talawdekar, A., Garikipati, S., Varley, I., Sionis, S., Beasley, N., Jackson, R., 2021. **A single centre's experience of 23 cases of total rhinectomy for the treatment of squamous cell carcinoma involving the nasal vestibule.** Eur Arch Otorhinolaryngol. <https://doi.org/10.1007/s00405-021-06972-6> - IF : 2.503 (cat C, Q2)
14. Charra-Brunaud, C., Salleron, J., Menoux, I., Peignaux, K., Ducassou, A., Petit, A., Pommier, P., Barillot, I., Serre, A.A., Thomas, L., Delannes, M., Thibouw, D., Antoni, D., Renard, S., Peiffert, D., 2021. **[Dose optimization in 3D pulsed dose rate brachytherapy for patients with locally advanced cervical cancer: A French multicenter phase II trial].** Cancer Radiother S1278-3218(21)00129–3. <https://doi.org/10.1016/j.canrad.2021.06.030> – IF : 1.018 (cat E, Q4)
15. Chebaro, A., Buc, E., Durin, T., Chiche, L., Brustia, R., Didier, A., Pruvot, F.-R., Kitano, Y., Muscari, F., Lecolle, K., Sulpice, L., Sonmez, E., Bougard, M., Amrani, M.E., Sommacale, D., Maulat, C., Ayav, A., Adam, R., Laurent, C., Truant, S., 2021. **Liver Venous Deprivation (LVD) or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)?: A Retrospective Multicentric Study.** Ann Surg. <https://doi.org/10.1097/SLA.0000000000005121> - IF : 12.969 (cat A, Q1)
16. Chollet, C., Malloizel-Delaunay, J., Cabarrou, B., Chantalat, E., Leray, H., Garmy-Susini, B., Yannoutsos, A., Chaput, B., Vaysse, C., 2021. **Liposuction-assisted brachioplasty in breast cancer-related lymphedema: Impact on volume reduction and quality of life.** J Plast Reconstr Aesthet Surg 74, 1633–1701. <https://doi.org/10.1016/j.bjps.2020.11.025> - IF : 2.74 (cat C, Q2)
17. Claps, F., van de Kamp, M.W., Mayr, R., Bostrom, P.J., Boormans, J.L., Eckstein, M., Mertens, L.S., Boevé, E.R., Neuzillet, Y., Burger, M., Pouessel, D., Trombetta, C., Wullich, B., van der Kwast, T.H., Hartmann, A., Allory, Y., Lotan, Y., Shariat, S.F., Zuiverloon, T.C.M., Mir, M.C., van Rhijn, B.W.G., 2021. **Risk factors associated with**

**positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.** World J Urol. <https://doi.org/10.1007/s00345-021-03776-5> – IF : 4.226 (cat B, Q1)

18. Corformat, M., Willekens, C., Vinit, J., Bussone, G., Fenaux, P., Fain, O., Klatzmann, D., Mekinian, A., Comont, T., MINHEMON (French network of dysimmune disorders associated to hematological malignancies), 2021. **Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.** Rheumatology (Oxford) 60, 3404–3408. <https://doi.org/10.1093/rheumatology/keaa696> - IF : 7.58 (cat B, Q1)
19. Coullomb, A., Pancaldi, V., 2021. **Tyссерand - Fast and accurate reconstruction of spatial networks from bioimages.** Bioinformatics btab490. <https://doi.org/10.1093/bioinformatics/btab490> - IF : 6.937 (cat A, Q1)
20. Dano, D., Lardy-Cleaud, A., Monneur, A., Quenel-Tueux, N., Levy, C., Mouret-Reynier, M.-A., Coudert, B., Mailliez, A., Ferrero, J.-M., Guiu, S., Campone, M., de La Motte Rouge, T., Petit, T., Pistilli, B., Dalenc, F., Simon, G., Lerebours, F., Chabaud, S., Bertucci, F., Gonçalves, A., 2021. **Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).** ESMO Open 6, 100220. <https://doi.org/10.1016/j.esmoop.2021.100220> - IF : 6.54 (cat B, Q1)
21. De Nonneville, A., Zemmour, C., Frank, S., Joly, F., Ray-Coquard, I., Costaz, H., Classe, J.-M., Floquet, A., De la Motte Rouge, T., Colombo, P.-E., Sauterey, B., Leblanc, E., Pomel, C., Marchal, F., Barranger, E., Savoye, A.-M., Guillemet, C., Petit, T., Pautier, P., Rouzier, R., Gladieff, L., Simon, G., Courtinard, C., Sabatier, R., 2021. **Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.** Gynecol Oncol S0090-8258(21)00581–3. <https://doi.org/10.1016/j.ygyno.2021.07.019> - IF : 5.482 (cat A, Q1)
22. Deflorenne, E., Peuchmaur, M., Vezzosi, D., Ajzenberg, C., Brunaud, L., Chevalier, N., Christin-Maitre, S., Decoudier, B., Driessens, N., Druil, D.D., Gilly, O., Goudet, P., Illouz, F., Jublanc, C., Lefebvre, H., Lopez, A.-G., Lussey, C., Morini, A., Raffin-Sanson, M.-L., Raingeard, I., Renoult-Pierre, P., Storey, C., Tabarin, A., Vantyghem, M.C., Vidal-Petiot, E., Baudin, E., Bertherat, J., Amar, L., 2021. **Adrenal ganglioneuromas: a retrospective multicentric study of 104 cases from the COMETE network.** Eur J Endocrinol 185, 463–474. <https://doi.org/10.1530/EJE-20-1049> - IF : 6.664 (cat B, Q1)

23. Di Perri, D., Jouglar, E., Blanc, E., Ducassou, A., Huchet, A., Vigneron, C., Escande, A., Chapet, S., Leseur, J., Bernier, V., Carrie, C., Martin, V., Claude, L., 2021. **Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study.** Br J Radiol 20210176. <https://doi.org/10.1259/bjr.20210176> – IF : 3.039 (cat D, Q2)
24. Dubot, P., Rafiq, M., Curot, J., Simonetta-Moreau, M., Sabourdy, F., Pettazzoni, M., Froissart, R., Levade, T., Ory-Magne, F., 2021. **A diagnosis of progressive myoclonic ataxia guided by blood biomarkers.** Parkinsonism Relat Disord S1353-8020(21)00247–9. <https://doi.org/10.1016/j.parkreldis.2021.06.027> - IF : 4.891 (cat B, Q1)
25. Dufour, C., Foulon, S., Geoffray, A., Masliah-Planchon, J., Figarella-Branger, D., Bernier-Chastagner, V., Padovani, L., Guerrini-Rousseau, L., Faure-Conter, C., Icher, C., Bertozzi, A.-I., Leblond, P., Akbaraly, T., Bourdeaut, F., André, N., Chappé, C., Schneider, P., De Carli, E., Chastagner, P., Berger, C., Lejeune, J., Soler, C., Entz-Werlé, N., Delisle, M.-B., 2021. **Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.** Neuro Oncol 23, 1163–1172. <https://doi.org/10.1093/neuonc/noaa301> - IF : 12.3 (cat A, Q1)
26. Girard, N., Marin, C., Hélias-Rodzewicz, Z., Villa, C., Julié, C., de Lajarte-Thirouard, A.-S., de Beauce, S.M., Lagorce-Pages, C., Renaud, F., Cazals-Hatem, D., Guedj, N., Cros, J., Raffin-Sanson, M.-L., Selves, J., Terris, B., Fléjou, J.-F., Garchon, H.-J., Coindre, J.-M., Emile, J.-F., 2021. **CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract.** Genes Chromosomes Cancer. <https://doi.org/10.1002/gcc.22981> - IF : 5.006 (cat B, Q1)
27. Girot, P., Baudin, E., Senellart, H., Bouarioua, N., Hentic, O., Guimbaud, R., Walter, T., Ferru, A., Roquin, G., Cadiot, G., Pracht, M., Girot, J.-B., Malka, D., Ducreux, M., Bennouna, J., Matysiak-Budnik, T., Hadoux, J., Touchefeu, Y., 2021. **Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French Group of Endocrine Tumors (GTE).** Neuroendocrinology. <https://doi.org/10.1159/000518650> – IF : 4.914 (cat C, Q2)
28. Greimel, E., Nagele, E., Lanceley, A., Oberguggenberger, A.S., Nordin, A., Kuljanic, K., Arraras, J.I., Wei-Chu, C., Jensen, P.T., Tomaszewski, K.A., Creutzberg, C.L., Galalae, R., Toelen, H., Zimmermann, K., Bjelic-Radisic, V., Costantini, A., Almont, T., Serpentine, S., Paskeviciute Frøding, L., Vistad, I., Schmalz, C., EORTC Quality of Life Group, 2021. **Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22).** Eur J

Cancer 154, 235–245. <https://doi.org/10.1016/j.ejca.2021.06.003> - IF : 9.162 (cat B, Q1)

29. Heeke, S., Benzaquen, J., Vallee, A., Allegra, M., Mazieres, J., Fayada, J., Rajamani, J., Lee, M., Ordinario, E., Tiotiu, A., Cadranel, J., Poudenx, M., Moro-Sibilot, D., Barlesi, F., Gervais, R., Thariat, J., Tanga, V., Boutros, J., Ilié, M., Hofman, V., Marquette, C.-H., Denis, M.G., Hofman, P., 2021. **Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay.** Ann Transl Med 9, 922. <https://doi.org/10.21037/atm-20-7900> – IF : 3.932 (cat C, Q3)
30. Hober, C., Fredeau, L., Pham-Ledard, A., Boubaya, M., Herms, F., Celerier, P., Aubin, F., Beneton, N., Dinulescu, M., Jannic, A., Meyer, N., Duval-Modeste, A.-B., Cesaire, L., Neidhardt, È.-M., Archier, É., Dréno, B., Lesage, C., Berthin, C., Kramkimel, N., Grange, F., de Quatrebarbes, J., Stoebner, P.-E., Poulalhon, N., Arnault, J.-P., Abed, S., Bonniaud, B., Darras, S., Heidelberger, V., Devaux, S., Moncourier, M., Misery, L., Mansard, S., Etienne, M., Brunet-Possenti, F., Jacobzone, C., Lesbazeilles, R., Skowron, F., Sanchez, J., Catala, S., Samimi, M., Tazi, Y., Spaeth, D., Gaudy-Marqueste, C., Collard, O., Triller, R., Pracht, M., Dumas, M., Peuvrel, L., Combe, P., Lauche, O., Guillet, P., Reguerre, Y., Kupfer-Bessagnet, I., Solub, D., Schoeffler, A., Bedane, C., Quéreux, G., Dalac, S., Mortier, L., Maubec, È., 2021. **Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.** Cancers (Basel) 13, 3547. <https://doi.org/10.3390/cancers13143547> - IF : 6.639 (cat B, Q1)
31. Hughes, B.G.M., Munoz-Couselo, E., Mortier, L., Bratland, Å., Gutzmer, R., Roshdy, O., Mendoza, R.G., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R.F., Grob, J.-J., 2021. **Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial.** Ann Oncol S0923-7534(21)02186–4. <https://doi.org/10.1016/j.annonc.2021.07.008> - IF : 32.976 (cat A, Q1)
32. Iv, F., Martins, C.S., Castro-Linares, G., Taveneau, C., Barbier, P., Verdier-Pinard, P., Camoin, L., Audebert, S., Tsai, F.-C., Ramond, L., Llewellyn, A., Belhabib, M., Nakazawa, K., Di Cicco, A., Vincentelli, R., Wenger, J., Cabantous, S., Koenderink, G.H., Bertin, A., Mavrakis, M., 2021. **Insights into animal septins using recombinant human septin octamers with distinct SEPT9 isoforms.** J Cell Sci jcs.258484. <https://doi.org/10.1242/jcs.258484> - IF : 5.285 (cat C, Q2)
33. Jiao, Y., Lesueur, F., Azencott, C.-A., Laurent, M., Mebirouk, N., Laborde, L., Beauvallet, J., Dondon, M.-G., Eon-Marchais, S., Laugé, A., GEMO Study Collaborators, GENEPSO

Study Collaborators, Noguès, C., Andrieu, N., Stoppa-Lyonnet, D., Caputo, S.M., 2021. [collab : Gladieff, L.] **A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers.** BMC Med Res Methodol 21, 155. <https://doi.org/10.1186/s12874-021-01299-6> – IF : 4.615 (cat B, Q1)

34. Juntas Morales, R., Perrin, A., Solé, G., Lacourt, D., Pegeot, H., Walther-Louvier, U., Cintas, P., Cances, C., Espil, C., Theze, C., Zenagui, R., Yauy, K., Cosset, E., Renard, D., Rigau, V., Maues de Paula, A., Uro-Coste, E., Arne-Bes, M.-C., Martin Négrier, M.-L., Leboucq, N., Acket, B., Malfatti, E., Biancalana, V., Metay, C., Richard, P., Rendu, J., Rivier, F., Koenig, M., Cossée, M., 2021. **An Integrated Clinical-Biological Approach to Identify Interindividual Variability and Atypical Phenotype-Genotype Correlations in Myopathies: Experience on A Cohort of 156 Families.** Genes (Basel) 12, 1199. <https://doi.org/10.3390/genes12081199> – IF : 4.096 (cat C, Q2)

35. Kastritis, E., Palladini, G., Minnema, M.C., Wechalekar, A.D., Jaccard, A., Lee, H.C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C.P., Lu, J., Schönland, S., Gatt, M.E., Suzuki, K., Kim, K., Cibeira, M.T., Beksac, M., Libby, E., Valent, J., Hungria, V., Wong, S.W., Rosenzweig, M., Bumma, N., Huart, A., Dimopoulos, M.A., Bhutani, D., Waxman, A.J., Goodman, S.A., Zonder, J.A., Lam, S., Song, K., Hansen, T., Manier, S., Roeloffzen, W., Jamroziak, K., Kwok, F., Shimazaki, C., Kim, J.-S., Crusoe, E., Ahmadi, T., Tran, N., Qin, X., Vasey, S.Y., Tromp, B., Schechter, J.M., Weiss, B.M., Zhuang, S.H., Vermeulen, J., Merlini, G., Comenzo, R.L., ANDROMEDA Trial Investigators, 2021. [collab : Huynh, A.] **Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.** N Engl J Med 385, 46–58. <https://doi.org/10.1056/NEJMoa2028631> - IF : 91.245 (cat A+, Q1)

36. Khalifa, J., Sargos, P., 2021. **In Regard to Marcq et al.** Int J Radiat Oncol Biol Phys 110, 916–917. <https://doi.org/10.1016/j.ijrobp.2021.01.058> - IF : 7.038 (cat A, Q1)

37. Lacaze, J.-L., Aziza, R., Chira, C., De Maio, E., Izar, F., Jouve, E., Massabeau, C., Pradines, A., Selmes, G., Ung, M., Zerdoud, S., Dalenc, F., 2021. **Diagnosis, biology and epidemiology of oligometastatic breast cancer.** Breast 59, 144–156. <https://doi.org/10.1016/j.breast.2021.06.010> – IF : 4.38 (cat B, Q1)

38. Langlais, T., Gomez-Brouchet, A., Accadbled, F., Compagnon, R., Pasquet, M., 2021. **A leg nodule in a 4-month-old girl.** Pediatr Dermatol 38, 677–679. <https://doi.org/10.1111/pde.14584> - IF : 1.588 (cat D, Q3)

39. Lapierre, L., Pericart, S., Protin, C., Borel, C., Ysebaert, L., Laurent, C., Oberic, L., 2021. **Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.** *Leuk Lymphoma* 1–3. <https://doi.org/10.1080/10428194.2021.1950711> – *IF : 3.28 (cat D, Q3)*
40. Larose, H., Prokoph, N., Matthews, J.D., Schleder, M., Högler, S., Alsulami, A.F., Ducray, S.P., Nuglozeh, E., Fazaludeen, F.M.S., Elmouna, A., Ceccon, M., Mologni, L., Gambacorti-Passerini, C., Hoefler, G., Lobello, C., Pospisilova, S., Janikova, A., Woessmann, W., Damm-Welk, C., Zimmermann, M., Federova, A., Malone, A., Smith, O., Wasik, M., Inghirami, G., Lamant, L., Blundell, T.L., Klapper, W., Merkel, O., Burke, A.G.A., Mian, S., Ashankyty, I., Kenner, L., Turner, S.D., 2021. **Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.** *Haematologica* 106, 1693–1704. <https://doi.org/10.3324/haematol.2019.238766> - *IF : 9.941 (cat A, Q1)*
41. Leste, J., Medjahed, I., Chauvin, M., Younes, T., Vieilleveigne, L., Ferrand, R., Franceries, X., Bardies, M., Simon, L., 2021. **A study of the interplay effect in radiation therapy using a Monte-Carlo model.** *Phys Med* 87, 73–82. <https://doi.org/10.1016/j.ejmp.2021.05.019> - *IF : 2.685 (cat D, Q3)*
42. Lesueur, F., Eon-Marchais, S., Bonnet-Boissinot, S., Beauvallet, J., Dondon, M.-G., Golmard, L., Rouleau, E., Garrec, C., Martinez, M., Toulas, C., Nguyen, T.D., Brayotel, F., Crivelli, L., Maugard, C.M., Bubien, V., Sevenet, N., Gesta, P., Chieze-Valero, S., Nambot, S., Goussot, V., Mari, V., Popovici, C., Prieur, F., Morin-Meschin, M.-E., Tinat, J., Lortholary, A., Dreyfus, H., Bidart, M., Collonge-Rame, M.-A., Mozelle-Nivoix, M., Gladiéff, L., Giraud, S., Boutry-Kryza, N., Chiesa, J., Denizeau, P., Bignon, Y.-J., Uhrhammer, N., Cohen-Haguénauer, O., Vilquin, P., Mailliez, A., Coupier, I., Rey, J.-M., Lacaze, E., Béra, O., Colas, C., Coulet, F., Delnatte, C., Houdayer, C., Lasset, C., Lemonnier, J., Longy, M., Noguès, C., Stoppa-Lyonnet, D., Vaur, D., Andrieu, N., Caron, O., 2021. **TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.** *Cancers (Basel)* 13, 3659. <https://doi.org/10.3390/cancers13153659> – *IF : 6.639 (cat B, Q1)*
43. Letestu, R., Dahmani, A., Boubaya, M., Baseggio, L., Campos, L., Chatelain, B., Debliquis, A., Drénou, B., Jacob, M.-C., Legac, E., Le Garff-Tavernier, M., Lhoumeau, A.-C., Quiney, C., Robillard, N., Ticchioni, M., Aanei, C., Katsahian, S., Delepine, R., Vaudaux, S., Rouillé, V., Béné, M.-C., Dartigeas, C., Van Den Neste, E., Leprêtre, S., Feugier, P., Cartron, G., Leblond, V., Lévy, V., Cymbalista, F., French Innovative Leukemia Organization (FILO), [collab : Ysebaert, L.] 2021. **Prognostic value of high-sensitivity measurable residual disease assessment after front-line**

**chemoimmunotherapy in chronic lymphocytic leukemia.** *Leukemia* 35, 1597–1609.  
<https://doi.org/10.1038/s41375-020-01009-z> – IF : 11.528 (cat A, Q1)

44. Lindsay, C.R., Garassino, M.C., Nadal, E., Öhrling, K., Scheffler, M., Mazières, J., 2021. **On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.** *Lung Cancer* 50169-5002(21)00474–8.  
<https://doi.org/10.1016/j.lungcan.2021.07.005> – IF : 5.705 (cat B, Q1)
45. Luna-Yolba, R., Marmoiton, J., Gigo, V., Marechal, X., Boet, E., Sahal, A., Alet, N., Abramovich, I., Gottlieb, E., Visentin, V., Paillasse, M.R., Sarry, J.-E., 2021. **Disrupting Mitochondrial Electron Transfer Chain Complex I Decreases Immune Checkpoints in Murine and Human Acute Myeloid Leukemic Cells.** *Cancers (Basel)* 13, 3499.  
<https://doi.org/10.3390/cancers13143499> - IF : 6.639 (cat B, Q1)
46. Mallet, E., Angeles, M.A., Cabarrou, B., Chardin, D., Viau, P., Frigenza, M., Navarro, A.S., Ducassou, A., Betrian, S., Martínez-Gómez, C., Tanguy Le Gac, Y., Chantalat, E., Motton, S., Ferron, G., Barranger, E., Gabiache, E., Martinez, A., 2021. **Performance of Multiparametric Functional Imaging to Assess Peritoneal Tumor Burden in Ovarian Cancer.** *Clin Nucl Med.* <https://doi.org/10.1097/RLU.0000000000003785> - IF : 7.794 (cat A, Q1)
47. Martinez, T., Sarda, S., Dupret-Bories, A., Charvillat, C., Progetti, F., Drouet, C., 2021. **Toward a doxorubicin-loaded bioinspired bone cement for the localized treatment of osteosarcoma.** *Future Oncol.* <https://doi.org/10.2217/fon-2021-0128> – IF : 3.404 (cat D, Q3)
48. Mathevet, P., Guani, B., Ciobanu, A., Lamarche, E.M., Boutitie, F., Balaya, V., Lecuru, F., 2021. **Histopathologic Validation of the Sentinel Node Technique for Early-Stage Cervical Cancer Patients.** *Ann Surg Oncol* 28, 3629–3635.  
<https://doi.org/10.1245/s10434-020-09328-2> – IF : 5.344 (cat A, Q2)
49. Michallet, A.-S., Letestu, R., Le Garff-Tavernier, M., Aanei, C., Ticchioni, M., Dilhuydy, M.-S., Subtil, F., Rouille, V., Mahe, B., Laribi, K., Villemagne, B., Salles, G., Tournilhac, O., Delmer, A., Portois, C., Pegourie, B., Leblond, V., Tomowiak, C., De Guibert, S., Orsini Piocelle, F., Banos, A., Carassou, P., Cartron, G., Fornecker, L.-M., Ysebaert, L., Dartigeas, C., Truchan-Graczyk, M., Vilque, J.-P., Aurran, T., Cymbalista, F., Lepretre, S., Levy, V., Nguyen-Khac, F., Feugier, P., 2021. **A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.** *Blood* 137, 1019–1023. <https://doi.org/10.1182/blood.2020008164> – IF : 22.113 (cat A, Q1)

50. Mohty, M., Avet-Loiseau, H., Harousseau, J.-L., 2021. **Requirements for operational cure in multiple myeloma.** Blood blood.2021012854. <https://doi.org/10.1182/blood.2021012854> - IF : 22.113 (cat A, Q1)
51. Montfort, A., Virazels, M., Colacios, C., Meyer, N., Ségui, B., 2021. **Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.** Nat Rev Rheumatol. <https://doi.org/10.1038/s41584-021-00653-8> - IF : 20.543 (cat A, Q1)
52. Morschhauser, F., Dyer, M.J.S., Walter, H.S., Danilov, A.V., Ysebaert, L., Hodson, D.J., Fegan, C., Rule, S.A., Radford, J., Cartron, G., Bouabdallah, K., Davies, A.J., Spurgeon, S., Rajakumaraswamy, N., Li, B., Humeniuk, R., Huang, X., Bhargava, P., Jürgensmeier, J.M., Salles, G., 2021. **Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.** Leukemia 35, 2108–2113. <https://doi.org/10.1038/s41375-020-01108-x> – IF : 11.528 (cat A, Q1)
53. Nowosad, A., Jeannot, P., Callot, C., Creff, J., Perchey, R.T., Joffre, C., Codogno, P., Manenti, S., Besson, A., 2021. **Publisher Correction: p27 controls Ragulator and mTOR activity in amino acid-deprived cells to regulate the autophagy-lysosomal pathway and coordinate cell cycle and cell growth.** Nat Cell Biol. <https://doi.org/10.1038/s41556-021-00741-7> - IF : 28.824 (cat A, Q1)
54. Partouche, E., Yeh, R., Eche, T., Rozenblum, L., Carrere, N., Guimbaud, R., Dierickx, L.O., Rousseau, H., Dercle, L., Mokrane, F.-Z., 2021. **Updated Trends in Imaging Practices for Pancreatic Neuroendocrine Tumors (PNETs): A Systematic Review and Meta-Analysis to Pave the Way for Standardization in the New Era of Big Data and Artificial Intelligence.** Front Oncol 11, 628408. <https://doi.org/10.3389/fonc.2021.628408> - IF : 6.244 (cat C, Q2)
55. Pautier, P., Floquet, A., Chevreau, C., Penel, N., Guillemet, C., Delcambre, C., Cupissol, D., Selle, F., Isambert, N., Piperno-Neumann, S., Saada-Bouzid, E., Bertucci, F., Bompas, E., Alexandre, J., Collard, O., Lebrun-Ly, V., Soulier, P., Toulmonde, M., Le Cesne, A., Lacas, B., Duffaud, F., French Sarcoma Group, 2021. **A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.** ESMO Open 6, 100209. <https://doi.org/10.1016/j.esmoop.2021.100209> – IF : 6.54 (cat B, Q1)
56. Paviglianiti, A., Labopin, M., Blaise, D., Socié, G., Bulabois, C.E., Lioure, B., Ceballos, P., Blau, I.W., Guillerm, G., Maertens, J., Chevallier, P., Huynh, A., Turlure, P., Deconinck, E., Forcade, E., Nagler, A., Mohty, M., 2021. **Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease**

**prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.** Bone Marrow Transplant 56, 1077–1085.  
<https://doi.org/10.1038/s41409-020-01155-z> - *IF : 5.483 (cat B, Q1)*

57. Perrin, A., Juntas Morales, R., Chapon, F., Thèse, C., Lacourt, D., Pégeot, H., Uro-Coste, E., Giovannini, D., Leboucq, N., Mallaret, M., Lagrange, E., Rigau, V., Gaudon, K., Richard, P., Koenig, M., Métay, C., Cossée, M., 2021. **Novel dominant distal titinopathy phenotype associated with copy number variation.** Ann Clin Transl Neurol. <https://doi.org/10.1002/acn3.51434> – *IF : 4.511 (cat C, Q2)*

58. Poillet-Perez, L., White, E., 2021. **MDVs to the rescue: How autophagy-deficient cancer cells adapt to defective mitophagy.** Dev Cell 56, 2010–2012. <https://doi.org/10.1016/j.devcel.2021.06.022> - *IF : 12.27 (cat A, Q1)*

59. Remon, J., Girard, N., Novello, S., de Castro, J., Bigay-Game, L., Bernabé, R., Greillier, L., Mosquera, J., Cousin, S., Juan, O., Sampayo, M., Besse, B., 2021. **PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.** Clin Lung Cancer S1525-7304(21)00189–3. <https://doi.org/10.1016/j.clcc.2021.07.008> – *IF : 4.785 (cat C, Q2)*

60. Robin, M., Mhanna, L., Chaltiel, L., Plat, G., Héluain, V., Basset, C., Meilleroux, J., Filleron, T., Mazières, J., Hermant, C., Guibert, N., 2021. **Feasibility of comprehensive genotyping specimens from radial endobronchial ultrasonography and electromagnetic navigation bronchoscopy.** ERJ Open Res 7, 00942–02020. <https://doi.org/10.1183/23120541.00942-2020> - *IF : NC - JCI : 0.7*

61. Rubio, M.T., Varlet, P., Allain, V., Ballot, C., Cuffel, A., Deschamps, M., Ferrand, C., Foguene, J., Forcade, E., Huynh, A., Guihot, A., Latouche, J.-B., Lemarie, C., Martinroche, G., Morin, F., Nguyen, S., Schmit, K., Servais, S., Simonetta, F., Yakoub-Agha, I., Caillat Zucman, S., 2021. **[Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].** Bull Cancer S0007-4551(21)00205–8. <https://doi.org/10.1016/j.bulcan.2021.04.008> – *IF : 1.276 (cat E, Q4)*

62. San-Miguel, J.F., Avet-Loiseau, H., Paiva, B., Kumar, S.K., Dimopoulos, M.A.A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A.J., Usmani, S.Z., Cook, G., Cavo, M., Quach, H., Ukropec, J., Ramaswami, P., Pei, H., Qi, Mia, Sun, S., Wang, J., Krevvata, M., DeAngelis, N., Heuck, C., Van Rampelbergh, R., Kudva, A., Kobos, R., Qi, Ming, Bahlis, N.J., 2021. **Sustained Minimal Residual Disease Negativity With Daratumumab in**

**Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.** Blood blood.2020010439.  
<https://doi.org/10.1182/blood.2020010439> - **IF : 22.113 (cat A, Q1)**

63. Schrijver, L.H., Antoniou, A.C., Olsson, H., Mooij, T.M., Roos-Blom, M.-J., Azarang, L., Adlard, J., Ahmed, M., Barrowdale, D., Davidson, R., Donaldson, A., Eeles, R., Evans, D.G., Frost, D., Henderson, A., Izatt, L., Ong, K.-R., Bonadona, V., Coupier, I., Faivre, L., Fricker, J.-P., Gesta, P., van Engelen, K., Jager, A., Menko, F.H., Mourits, M.J.E., Singer, C.F., Tan, Y.Y., Foretova, L., Navratilova, M., Schmutzler, R.K., Ellberg, C., Gerdes, A.-M., Caldes, T., Simard, J., Olah, E., Jakubowska, A., Rantala, J., Osorio, A., Hopper, J.L., Phillips, K.-A., Milne, R.L., Beth Terry, M., Noguès, C., Engel, C., Kast, K., Goldgar, D.E., van Leeuwen, F.E., Easton, D.F., Andrieu, N., Rookus, M.A., Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study, [collab : [Gladiëff, L.](#)] 2021. **Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.** Am J Obstet Gynecol 225, 51.e1-51.e17. <https://doi.org/10.1016/j.ajog.2021.01.014> – **IF : 8.661 (cat A, Q1)**
64. Shao, W., Kuhn, C., Mayr, D., Ditsch, N., Kailuwait, M., Wolf, V., Harbeck, N., Mahner, S., Jeschke, U., Cavallès, V., [Sixou, S.](#), 2021a. **Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer.** J Cancer Res Clin Oncol. <https://doi.org/10.1007/s00432-021-03670-y> – ~~Shao, W., Kuhn, C., Mayr, D., Ditsch, N., Kailuwait, M., Wolf, V., Harbeck, N., Mahner, S., Jeschke, U., Cavallès, V., Sixou, S., 2021b. Correction in: Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer. J Cancer Res Clin Oncol. <https://doi.org/10.1007/s00432-021-03736-x>. **IF : 4.553 (cat C, Q2).**~~
65. [Siegfried, A.](#), [Delisle, M.-B.](#), 2021. [**Medulloblastoma. Pathology**]. Neurochirurgie 67, 28–38. <https://doi.org/10.1016/j.neuchi.2017.12.006> – **IF : 1.553 (cat E, Q4)**
66. [Srykh, C.](#), [Péricart, S.](#), Lamaison, C., [Escudié, F.](#), [Brousset, P.](#), [Laurent, C.](#), 2021. **Epstein-Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features.** Cancers (Basel) 13, 3315. <https://doi.org/10.3390/cancers13133315> - **IF : 6.639 (cat B, Q1)**
67. Tauziède-Espariat, A., Sievers, P., Larousserie, F., Benzakoun, J., Guillemot, D., Pierron, G., Duchesne, M., [Uro-Coste, E.](#), Roux, A., Vasiljevic, A., Fenouil, T., Meyronet, D., Mokhtari, K., Polivka, M., Rousseau, A., Bost-Bezeaud, F., Akoury, S., Pallud, J., Benevello, C., Hasty, L., Gareton, A., Lechapt, E., Chrétien, F., Blauwblomme, T., Beccaria, K., Puget, S., Sahm, F., Varlet, P., RENOCLIP-LOC, 2021. **An integrative**

**histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts.** Brain Pathol e13010. <https://doi.org/10.1111/bpa.13010> – IF : 6.508 (cat A, Q1)

68. Tournilhac, O., Le Garff-Tavernier, M., Nguyen Quoc, S., Forcade, E., Chevallier, P., Legrand-Izadifar, F., Laurent Damaj, G., Michonneau, D., Tomowiak, C., Borel, C., Orvain, C., Turlure, P., Redjou, R., Guillerm, G., Vincent, L., Simand, C., Lemal, R., Quiney, C., Combes, P., Pereira, B., Calvet, L., Cabrespine, A., Bay, J.-O., Leblond, V., Dhédin, N., Organization Filo, F.I.L., De Moelle Et de Thérapie Cellulaire Sfgm-Tc, S.F. de G., 2021. **Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.** Haematologica 106, 1867–1875. <https://doi.org/10.3324/haematol.2019.239566> – IF : 9.941 (cat A, Q1)
69. Trecourt, A., Mauduit, C., Szablewski, V., Fontaine, J., Balme, B., Donzel, M., Laurent, C., Sesques, P., Ghesquières, H., Bachy, E., Salles, G., Emile, J.-F., Chassagne-Clément, C., Genestier, L., Copie-Bergman, C., Traverse-Glehen, A., 2021. **Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.** Am J Surg Pathol. <https://doi.org/10.1097/PAS.0000000000001780> - IF : 6.394 (cat A, Q1)
70. Trimaglio, G., Tilkin-Mariamé, A.-F., Feliu, V., Lauzéral-Vizcaino, F., Tosolini, M., Valle, C., Ayyoub, M., Neyrolles, O., Vergnolle, N., Rombouts, Y., Devaud, C., 2020. **Colon-specific immune microenvironment regulates cancer progression versus rejection.** Oncoimmunology 9, 1790125. <https://doi.org/10.1080/2162402X.2020.1790125> - IF : 8.11 (cat B, Q1)
71. Ulrich, B., Pradines, A., Mazières, J., Guibert, N., 2021. **Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges.** Cancers (Basel) 13, 3759. <https://doi.org/10.3390/cancers13153759> - IF : 6.639 (cat B, Q1)
72. Wislez, M., Domblides, C., Greillier, L., Mazières, J., Monnet, I., Kiakouama-Maleka, L., Quantin, X., Spano, J.P., Ricordel, C., Fraisse, P., Janicot, H., Audigier-Valette, C., Amour, E., Langlais, A., Rabbe, N., Makinson, A., Cadranet, J., Laurent-Puig, P., Lavolé, A., Blons, H., 2021. **Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).** Lung Cancer 157, 124–130. <https://doi.org/10.1016/j.lungcan.2021.05.013> – IF : 5.705 (cat B, Q1)

73. Zati Zehni, A., Batz, F., Cavallès, V., Sixou, S., Kaltofen, T., Keckstein, S., Heidegger, H.H., Ditsch, N., Mahner, S., Jeschke, U., Vilsmaier, T., 2021. **Cytoplasmic Localization of RXR $\alpha$  Determines Outcome in Breast Cancer.** *Cancers (Basel)* 13, 3756. <https://doi.org/10.3390/cancers13153756> - IF : 6.639 (cat B, Q1)

74. Zeiser, R., Polverelli, N., Ram, R., Hashmi, S.K., Chakraverty, R., Middeke, J.M., Musso, M., Giebel, S., Uzay, A., Langmuir, P., Hollaender, N., Gowda, M., Stefanelli, T., Lee, S.J., Teshima, T., Locatelli, F., REACH3 Investigators, [collab : Huynh, A.] 2021. **Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.** *N Engl J Med* 385, 228–238. <https://doi.org/10.1056/NEJMoa2033122> – IF : 91.245 (cat A+, Q1)

